ROPIVACAINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ropivacaine Hydrochloride, and when can generic versions of Ropivacaine Hydrochloride launch?
Ropivacaine Hydrochloride is a drug marketed by Amneal, Caplin, Eugia Pharma, Gland Pharma Ltd, Hikma, Hospira, Inforlife, Mylan Labs Ltd, Navinta Llc, Rising, and Somerset Theraps Llc. and is included in thirteen NDAs.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ropivacaine Hydrochloride
A generic version of ROPIVACAINE HYDROCHLORIDE was approved as ropivacaine hydrochloride by NAVINTA LLC on July 17th, 2014.
Summary for ROPIVACAINE HYDROCHLORIDE
Recent Clinical Trials for ROPIVACAINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fayoum University Hospital | N/A |
The University of Texas Health Science Center at San Antonio | Phase 2 |
National Trauma Center | N/A |
Pharmacology for ROPIVACAINE HYDROCHLORIDE
Drug Class | Amide Local Anesthetic |
Physiological Effect | Local Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for ROPIVACAINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for ROPIVACAINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 200 mL | 020533 | 1 | 2015-09-03 |
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 100 mL | 020533 | 1 | 2015-01-30 |
NAROPIN | Injection | ropivacaine hydrochloride | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | 020533 | 1 | 2006-11-13 |